As this effect is more pronounced in RR-MS patients with disease activity during SFE treatment, the increase of 5-LO and 12/15-LO-derived LM might indicate that PPARγ-signalling is already upregulated in non-responding patients and thereby indirectly revealing one potential mechanism of action of the SFE in this trial. Here, PPARG is linked to myeloid sarcoma.